• Publications
  • Influence
D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures
D-23129 presents an orally active, safe, broad spectrum anticonvulsant agent, which is structurally unrelated to anticonVulsants currently used, and it is expected that D- 23129 will improve the treatment of refractory seizures in humans. Expand
The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells tranfected with human KCNQ2/3 subunits
The data display that retigabine is the first described M-Channel agonist and support the hypothesis that M-channel agonism is a new mode of action for anticonvulsant drugs. Expand
Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy.
The powerful antiepileptogenic activity of levetiracetam in the kindling model indicates that levetIRacetam is not only an interesting novel drug for symptomatic treatment of epilepsy but might be suited for pharmacological prevention of this disease in patients with a high prospective risk of the development of epilepsy. Expand
In Vivo Efficacy in Airway Disease Models of N-(3,5-Dichloropyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic Acid Amide (AWD 12-281), a Selective Phosphodiesterase 4 Inhibitor for
Results indicate that AWD 12-281 is a unique potential new drug for the topical treatment of asthma and COPD, and has a considerably lower emetic potential than cilomilast in ferrets and roflumilasts in pigs. Expand
The new anticonvulsant retigabine (D-23129) acts as an opener of K+ channels in neuronal cells.
  • C. Rundfeldt
  • Chemistry, Medicine
  • European journal of pharmacology
  • 8 October 1997
It can be expected that the K+ channel opening effect contributes to the anticonvulsant activity of retigabine. Expand
D-23129: a potent anticonvulsant in the amygdala kindling model of complex partial seizures.
It is demonstrated that D-23129 is more potent in the amygdala kindling model of complex partial seizures than in other seizure models, thus indicating that this compound has potential for antiepileptic therapy. Expand
Investigations into the mechanism of action of the new anticonvulsant retigabine. Interaction with GABAergic and glutamatergic neurotransmission and with voltage gated ion channels.
The action of retigabine was not antagonised by flumazenil indicating interaction with other than benzodiazepine binding sites, and the contribution of this mechanism to the anticonvulsant activity of retIGabine may be minor. Expand
The anti-hyperalgesic activity of retigabine is mediated by KCNQ potassium channel activation
The potassium channel opening properties of retigabine are critically involved in its ability to reduce neuropathic pain response and are concluded that the anti-allodynic effect can be inhibited by linopirdine. Expand
Clinical efficacy and safety of imepitoin in comparison with phenobarbital for the control of idiopathic epilepsy in dogs.
Results indicate that imepitoin is a potent and safe antiepileptic drug for dogs and comparable efficacy to phenobarbital in controlling seizures in dogs. Expand
Hemispheric asymmetries in spontaneous firing characteristics of substantia nigra pars reticulata neurons following a unilateral 6-hydroxydopamine lesion of the rat nigrostriatal pathway
In lesioned rats, the mean firing rate of SNR neurons at the lesioned side was significantly reduced and there was an increase in the occurrence of bursting activity, while firing rate in the contralateral SNR was significantly increased without change in the frequency of bursting neurons. Expand